ID: ALA4103353

Max Phase: Preclinical

Molecular Formula: C33H42N2O6

Molecular Weight: 562.71

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1ccc(OCCCN2CCOCC2)c(NC(=O)COc2ccc(C34CC5CC(CC(C5)C3)C4)cc2)c1

Standard InChI:  InChI=1S/C33H42N2O6/c1-38-32(37)26-3-8-30(40-12-2-9-35-10-13-39-14-11-35)29(18-26)34-31(36)22-41-28-6-4-27(5-7-28)33-19-23-15-24(20-33)17-25(16-23)21-33/h3-8,18,23-25H,2,9-17,19-22H2,1H3,(H,34,36)

Standard InChI Key:  SUWQBHNNQMVQBM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 562.71

Molecular Weight (Monoisotopic): 562.3043

AlogP: 5.06

#Rotatable Bonds: 11

Polar Surface Area: 86.33

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.43

CX Basic pKa: 6.92

CX LogP: 4.78

CX LogD: 4.66

Aromatic Rings: 2

Heavy Atoms: 41

QED Weighted: 0.30

Np Likeness Score: -1.23

References

1. Naik R, Ban HS, Jang K, Kim I, Xu X, Harmalkar D, Shin SA, Kim M, Kim BK, Park J, Ku B, Oh S, Won M, Lee K..  (2017)  Methyl 3-(3-(4-(2,4,4-Trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a Novel and Dual Malate Dehydrogenase (MDH) 1/2 Inhibitor Targeting Cancer Metabolism.,  60  (20): [PMID:28991459] [10.1021/acs.jmedchem.7b01231]

Source

Source(1):

• Scientific Literature